| Dr Nicola Corvaja, MD | |
|
161 Fort Washington Ave, New York, NY 10032-3729 | |
| (212) 342-3616 | |
| Not Available |
| Full Name | Dr Nicola Corvaja |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Interventional Cardiology |
| Location | 161 Fort Washington Ave, New York, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003988643 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nicola Corvaja, MD 1980 Crompond Rd Ste 3r, Cortlandt Manor, NY 10567-4144 Ph: (914) 734-3550 | Dr Nicola Corvaja, MD 161 Fort Washington Ave, New York, NY 10032-3729 Ph: (212) 342-3616 |
News Archive
Medical schools are changing to adapt to the shifting medical landscape around America by increasingly preparing students for alternative methods of care, increased demand for their services and a world where health care reform will likely soon change the landscape again, The Washington Post reports.
An innovative drug with a new mechanism of action that may be effective against a range of cancers will enter the first phase of clinical trials, it was announced today (Monday) at Cancer Research UK's Senior Researchers Meeting.
Elsevier, a world-leading provider of scientific, technical, and medical information products and services, today announced the launch of the International Journal of Surgery Open (IJS Open), a new open access journal covering all areas of surgery.
Researchers at Umeå University in Sweden have discovered unique muscle fibers in the soft palate of the mouth in both infants and adults. The fibers seem to be present in greater number in snorers and sleep apnea patients.
Serono and IVAX Corporation has announced positive results from two clinical trials with a new proprietary oral formulation of cladribine, a potential new treatment for multiple sclerosis (MS). The study results showed that the formulation of oral cladribine which has been developed by Serono and IVAX has met the targets for an orally administered product, with blood levels of cladribine in the expected therapeutic range. Efficacy studies of oral cladribine in MS patients are planned to start late 2004.
› Verified 7 days ago
Dr. Ravishankar Ramaswamy, MD, MS Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1440 Madison Avenue, New York, NY 10029 Phone: 212-659-8552 Fax: 212-860-9737 | |
Dr. Pietro Alessandro Ambrogio Canetta, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 622 W 168th St, Ph4-124, New York, NY 10032 Phone: 212-305-5020 Fax: 212-305-6692 | |
Dr. Rakhshan Mahmood Chida, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 327 E 17th St, New York, NY 10003 Phone: 212-420-5690 | |
Charles D Resor, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 622 W 168th St, New York, NY 10032 Phone: 212-305-2913 | |
Dr. Jacqueline Yuey Lonier, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1150 Saint Nicholas Ave, New York, NY 10032 Phone: 212-851-5494 | |
Dr. Sharon Uralil, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 550 1st Ave, New York, NY 10016 Phone: 212-263-3293 | |
Diana Kantor, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 775 9th Ave, New York, NY 10019 Phone: 212-586-1550 |